Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 12,000 possible US Trogarzo patients?

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jun 23, 2022 11:02am

144 Views

Post# 34777025

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:12,000 possible US Trogarzo patients?

As I have noted many times, Bloomberg is not super accurate. I am not sure how they end up with rukobia at arounf $7 per month when the company states $16 per quarter though!

qwerty22 wrote:
I'm pulling numbers from GSK's quarterly reports. For example Q1 2022, table on page 24, definitely says 3 months total $16 million, $15 million US, $1 million Europe.

https://www.gsk.com/media/7639/q1-2022-announcement.pdf

SPCEO1 wrote: I will try to get those copied in properly when I have a chance. Trogarzo monthly sales running near $2 million and Rukobia around $7 million.

SPCEO1 wrote:

SPCEO1 wrote: Here is what Bloomberg (Symphony) say Trogarzo and Rukobia sales have been:

[img]https://https://imgur.com/0bLWrF3[/img]

[img]https://https://imgur.com/MsX5Uqt[/img]

qwerty22 wrote:
ok, yes, I ended up down a rabbit hole of Rukobia sales.

USA sales

Q1 2021 $7 mil
Q2 2021 $10 mil
Q3 2021 $15 mil
Q4 2021 $14 mil
Q1 2022 $15 mil

Got established (probably payor thing) then no growth over 3 Qs.

qwerty22 wrote:

Just on where Rukobia sales are going.

From what I can see GSK reported USA sales of $15 mil in 3rd Q and $14 mil in 4th Q. I guess 2022 wasn't quite a full year for this new drug.

This is trogarzo's main rival for MDR patients that need new options. As I said their absolute number is higher probably because they started with a much bigger pool of patients from their clinical trial but it doesn't look like there's much growth going on.

qwerty22 wrote:

GSK generated $43 mil in sales of fostemsavir (Rukobia) in the first year They had much larger clinical trials and the difference between their sales and THTX could easily just be the number of patients that flipped over from getting the drug for free to buying it on the market when it got approved. If anybody is patient enough we can wait see what happens in year 2 to their sales growth.

I really just don't expect that 12,000 headline number for potential patients captures the reality of the situation. Viiv's own research showed most MDR patients stable on the pre-existing hiv drugs, especially the newest ones. I don't think this is about THTX failing to execute, the market is just more limited than this 12,000 number leads you to think.

(Rukobia numbers on page 16)

https://www.gsk.com/media/7377/fy-2021-results-announcement.pdf

jeffm34 wrote:

I would like to see a cost comparison on the different treatment options. I think Taimed has priced the product out of the market like they have in Europe. Maybe try selling the drug at a reasonable price. If you cut the price in half could you at least double the number of patients?

SPCEO1 wrote: All of us would but don't bet on it. If something like that number of patients were possible it likely would have happened in the first couple of years when Trogarzo was on the market without any competition.

Bucknelly21 wrote: Id be happy with 1k of those 12k